

**STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

Docket No.
2290.00061

In Re Application Of: **Sara Lavi**

Serial No.
09/029,479

Filing Date
10/21/98

Examiner
Woitach, J.

Group Art Unit
1632

Invention:

**MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE 2C-PP2Ca-EXPRESSION IN TUMOR
CELLS FOR CANCER DETECTION AND THERAPY**

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☐ Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Statement Under 37 CFR 1.97(e)(2)


- ☒ No item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.


Signature

Dated: **July 5, 2001**

**Amy E. Rinaldo, Reg. No. 45,791
Kohn & Associates
30500 Northwestern Highway, Suite 410
Farmington Hills, Michigan 48334
(248) 539-5050**

I certify that this document is being deposited on
7/5/01 with the U.S. Postal Service as first
class mail under 37 C.F.R. 1.8 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C.
20231.


Signature of Person Mailing Correspondence

Connie Herty

Typed or Printed Name of Person Mailing Correspondence

cc:



Form PTO-1449 S U P P L E M E N T A L I N F O R M A T I O N D I S C L O S U R E C I T A T I O N I N A N A P P L I C A T I O N <i>(Use several sheets if necessary)</i>										Docket Number (Optional) 2290.00061					Application Number 09/029,479						
										Applicant Sara Lavi											
										Filing Date 10/21/98					Group Art Unit 1632						
U.S. PATENT DOCUMENTS																					
EXAMINER INITIAL		DOCUMENT NUMBER								DATE		NAME				CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS																					
		DOCKET NUMBER								DATE		COUNTRY				CLASS		SUBCLASS		TRANSLATION	
																				YES	NO
OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)																					
		Fukushige S, Sauer B. "Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells. Proc Natl Acad Sci Usa 1992 Sep 1;89 (17):7905-9.																			
		Gage PJ et al. "A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J. Virol 1992 Sep; 66 (9):5509-15.																			
		Holt CL and May GS. "A novel phage lambda replacement Cre-lox vector that has automatic subcloning capabilities." Gene. 1993 Oct 29;133 (1):95-7.																			
EXAMINER										DATE CONSIDERED											
<p>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.</p>																					